Thyroid Receptor Restoration Boosts CAR‑T Therapy in Aggressive Tumors

Mayo Clinic researchers have announced a new strategy that could help chimeric antigen receptor‑T cell (CAR‑T) therapy overcome a key obstacle in treating solid tumors. The team found a way to counteract the ability of cancer cells to alter their surface proteins, a change that allows them to evade the engineered immune cells designed to seek and destroy them.

In their study, the investigators engineered CAR‑T cells to recognize multiple tumor antigens simultaneously, thereby reducing the likelihood that a single genetic alteration in the cancer would render the therapy ineffective. The approach also includes a safety switch that can be activated if the cells begin to attack healthy tissue, addressing concerns about off‑target effects that have limited CAR‑T use beyond blood cancers. The findings were published in a peer‑reviewed journal and were supported by preclinical models that demonstrated sustained tumor regression in mice bearing heterogeneous solid tumors.

If the strategy translates to human trials, it could broaden the applicability of CAR‑T therapy to a wider range of cancers, including those that have historically been resistant to immunotherapy. The research team plans to initiate early‑phase clinical studies next year, aiming to evaluate the safety and efficacy of the multi‑antigen CAR‑T cells in patients with advanced solid tumors.